Keyphrases
Tacrolimus
100%
Kidney Transplant Recipients
84%
Hematopoietic Cell Transplantation
66%
Mycophenolic Acid
62%
Pharmacokinetics
58%
Graft-versus-host Disease (GvHD)
43%
Genetic Variants
43%
Mycophenolate Mofetil
42%
Pharmacogenomics
40%
Acute Rejection
38%
African American
33%
Area under the Curve
32%
Transplantation
31%
Single nucleotide Polymorphism
31%
Trough Concentration
31%
Kidney Transplant
30%
Cyclophosphamide
30%
CYP3A5
29%
Mycophenolate
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Genotype
24%
Kidney Transplantation
23%
Hematopoietic Cell Transplant
22%
Clinical Factors
21%
Minnesota
21%
Polygenic Risk Score
20%
Voriconazole
20%
Haematopoietic Stem Cell Transplant Recipients
19%
Cyclosporine
19%
Genome-wide Association Study
19%
Transplant Patients
18%
Pediatric
18%
Cytochrome P450 3A4 (CYP3A4)
17%
Fludarabine
17%
Metabolism
16%
Reduced-intensity Conditioning
16%
PGx Testing
15%
Enterohepatic Recirculation
14%
Native American
14%
Polymorphism
14%
Dose Requirement
14%
SNP
13%
Calcineurin Inhibitors
13%
Kidney Allograft
13%
Drug Interactions
12%
Transplant Outcomes
12%
Personalized Medicine
12%
Hematopoietic Stem Cell Transplantation
11%
Pharmacogenetics
11%
Oral Liquid
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
80%
Mycophenolic Acid
73%
Tacrolimus
71%
Mycophenolate Mofetil
32%
Cyclophosphamide
30%
Cytochrome P450 3A5
28%
Pharmacogenomics
26%
Voriconazole
19%
Acute Graft Versus Host Disease
17%
Fludarabine
16%
Ciclosporin
16%
CYP3A4
13%
Calcineurin Inhibitor
13%
Diseases
13%
Immunosuppressive Agent
13%
Graft Versus Host Reaction
12%
Pharmacotherapy
12%
Phosphoramide Mustard
11%
Creatinine
11%
Acute Graft Rejection
11%
Pharmacogenetics
9%
Clinical Trial
9%
Vidarabine
9%
Hematologic Malignancy
8%
Rapamycin
8%
Microbiome
7%
High Performance Liquid Chromatography
7%
Isradipine
7%
Doxorubicin
7%
Busulfan
7%
Amino Acid
7%
Breast Cancer
7%
Fluconazole
7%
Coronavirinae
7%
Ganciclovir
7%
Fanconi Anemia
7%
CYP2B6
7%
Glucuronide
7%
Clofarabine
7%
Elimination
6%
Hydroxychloroquine
6%
Graft Failure
6%
Leukopenia
6%
Infection
5%
CYP2C19
5%
Chemotherapy
5%
Bioavailability
5%
Nephrotoxicity
5%
Anemia
5%